These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26679694)

  • 1. Survivin contributes to DNA repair by homologous recombination in breast cancer cells.
    Véquaud E; Desplanques G; Jézéquel P; Juin P; Barillé-Nion S
    Breast Cancer Res Treat; 2016 Jan; 155(1):53-63. PubMed ID: 26679694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
    Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
    Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
    Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
    BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
    BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin safeguards chromosome numbers and protects from aneuploidy independently from p53.
    Wiedemuth R; Klink B; Töpfer K; Schröck E; Schackert G; Tatsuka M; Temme A
    Mol Cancer; 2014 May; 13():107. PubMed ID: 24886358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
    Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
    Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
    Villamar Cruz O; Prudnikova TY; Araiza-Olivera D; Perez-Plasencia C; Johnson N; Bernhardy AJ; Slifker M; Renner C; Chernoff J; Arias-Romero LE
    Oncotarget; 2016 Nov; 7(47):76590-76603. PubMed ID: 27740936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells.
    Conde M; Michen S; Wiedemuth R; Klink B; Schröck E; Schackert G; Temme A
    BMC Cancer; 2017 Dec; 17(1):889. PubMed ID: 29282022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
    Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
    Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
    Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
    Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
    Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
    Bridges KA; Toniatti C; Buser CA; Liu H; Buchholz TA; Meyn RE
    Oncotarget; 2014 Jul; 5(13):5076-86. PubMed ID: 24970803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells.
    Vernole P; Muzi A; Volpi A; Dorio AS; Terrinoni A; Shah GM; Graziani G
    Mutat Res; 2009 May; 664(1-2):39-47. PubMed ID: 19428379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells.
    Choi YE; Park E
    J Nutr Biochem; 2015 Dec; 26(12):1442-7. PubMed ID: 26350251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor.
    Philip KT; Dutta K; Chakraborty S; Patro BS
    Int J Biochem Cell Biol; 2023 Aug; 161():106443. PubMed ID: 37392863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51.
    Zhao L; Si CS; Yu Y; Lu JW; Zhuang Y
    Cancer Sci; 2019 Nov; 110(11):3543-3552. PubMed ID: 31541611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.